OUTPACE Trademark

Trademark Overview


On Friday, January 17, 2025, a trademark application was filed for OUTPACE with the United States Patent and Trademark Office. The USPTO has given the OUTPACE trademark a serial number of 99007063. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, October 1, 2025. This trademark is owned by Outpace Bio, Inc.. The OUTPACE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; pharmaceutical drug development services; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; medical and scientific research and development services, namely, identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical and scientific research and development services, namely, identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; medical and scientific research and development services, namely, protein engineering and design s...
outpace

General Information


Serial Number99007063
Word MarkOUTPACE
Filing DateFriday, January 17, 2025
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, October 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDrug discovery services; pharmaceutical drug development services; product research and development; scientific research and development services; pharmaceutical research and development; development of pharmaceutical preparations and drugs; medical and scientific research and development services, namely, identification, production and development of therapeutics, cell therapies, bioengineered cells and proteins for the treatment and prevention of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical and scientific research and development services, namely, identification, production and development of cell therapy solutions, namely protein design and custom cell programming; scientific, medical, biotechnology, biomedical, and pharmaceutical research, development, testing and analysis services; medical and scientific research and development services, namely, protein engineering and design services; scientific and medical services, namely, human cell programming services; scientific research, development, discovery and consulting services in the fields of cell therapy and immuno-oncology; scientific research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical research; clinical research in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; scientific research and development, scientific laboratory services, medical and scientific research, biotechnology research and synthetic biology research, all of the foregoing relating to human beings; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; development of pharmaceutical preparations and drugs in the field of gene therapy; medical research laboratory services, namely, biological tissue material processing and analysis in the field of cell therapy and immuno-oncology; biotechnology scientific laboratory services; scientific and medical research laboratory services; genetic engineering services, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; genetic engineering of biological cells, cellular targets, proteins, and antibodies for others; providing a website featuring information in the scientific, medical, biotechnology, biomedical, and pharmaceutical fields for the prevention and treatment of human diseases, disorders and conditions; provision of information about scientific and medical research in the field of drug discovery, development and testing; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of drug discovery, development and testing; provision of information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; providing a website featuring information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of the prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; provision of information about prevention and treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of cell therapy and immuno-oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing a website featuring information about treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders in the field of pharmaceuticals and clinical trials; provision of scientific and medical research information in the fields of biotechnology, biomedical, and pharmaceuticals; providing information about medical research relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of human diseases, disorders and conditions;

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 17, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOutpace Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98109

Trademark Events


Event DateEvent Description
Friday, January 17, 2025NEW APPLICATION ENTERED
Friday, January 17, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 27, 2025ASSIGNED TO EXAMINER
Thursday, July 3, 2025NON-FINAL ACTION WRITTEN
Thursday, July 3, 2025NON-FINAL ACTION E-MAILED
Thursday, July 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 1, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 1, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 1, 2025TEAS/EMAIL CORRESPONDENCE ENTERED